Polymorphisms in drug transporter and metabolism genes associated with resistance to imatinib in chronic myeloid leukemia: A systematic review and meta analysis
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Arrieta Gómez, Ana Marcela | |
| dc.contributor.author | Díaz-Mendoza, María Antonia | |
| dc.contributor.author | Bello Lemus, Yesit | |
| dc.contributor.author | León-Mejía, Grethel | |
| dc.contributor.author | Ruiz Benitez, Martha Lucia | |
| dc.date.accessioned | 2024-06-24T22:24:49Z | |
| dc.date.available | 2024-06-24T22:24:49Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | The aim of this study was to establish the relationship between different polymorphisms in drug transporter and metabolizer genes and resistance to imatinib in chronic myeloid leukemia (CML). For this purpose, an exhaustive search was carried out in the Scopus, Web of Science, and PubMed databases using different combinations of keywords with different inclusion and exclusion criteria. The meta-analysis included nine studies that met the established criteria. The results of the study showed that the polymorphic variants AG and GG of CYP3A5*3 are associated with response to treatment, presenting a significantly lower risk with resistance to imatinib. Likewise, the variants T1236C and G2677T/A of the ABCB1 gene show a significant association with treatment efficacy. In addition, the genetic polymorphism 1236T, homozygous CC of the MDR1 gene, significantly influences the increased risk of cytogenetic relapse and the polymorphic variant 361G>A GA of the SLCO1A2 gene significantly affects the complete molecular response. | eng |
| dc.format.mimetype | ||
| dc.identifier.citation | Gómez, A.M.A.; Díaz-Mendoza, M.A.; Lemus, Y.B.; León-Mejía, G.; Benitez, M.L.R. Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Sci. Pharm. 2024, 92, 2. https://doi.org/10.3390/ scipharm92010002 | eng |
| dc.identifier.doi | https://doi.org/10.3390/scipharm92010002 | |
| dc.identifier.issn | 22180532 (On line) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/14767 | |
| dc.identifier.url | https://www.mdpi.com/2218-0532/92/1/2 | |
| dc.language.iso | eng | |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | MDPI | eng |
| dc.publisher | Facultad de Ciencias Básicas y Biomédicas | spa |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
| dc.source | Scientia Pharmaceutica | eng |
| dc.source | Sci. Pharm | eng |
| dc.source | Vol. 92 No. 1, (2024) | |
| dc.subject.keywords | LMC | eng |
| dc.subject.keywords | Philadelphia chromosome | eng |
| dc.subject.keywords | Polymorphism | eng |
| dc.subject.keywords | Translocation | eng |
| dc.subject.keywords | Resistance | eng |
| dc.subject.keywords | Meta-analysis | eng |
| dc.title | Polymorphisms in drug transporter and metabolism genes associated with resistance to imatinib in chronic myeloid leukemia: A systematic review and meta analysis | eng |
| dc.type.driver | info:eu-repo/semantics/masterThesis | |
| dc.type.spa | Trabajo de grado máster | |
| dcterms.references | Abdulmawjood, B.; Costa, B.; Roma-Rodrigues, C.; Baptista, P.V.; Fernandes, A.R. Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far? Natl. Libr. Med. 2021, 22, 12516. | eng |
| dcterms.references | Thompson, P.A.; Kantarjian, H.M.; Cortes, J.E. Diagnosis and treatment of chronic myeloid leukemia (CML) in 2015. Natl. Libr. Med. 2015, 10, 1440–1454. | eng |
| dcterms.references | Orozco, J.; Valencia, J.E.; Aiello, E.; Ribón, G.; Guerrero, F.; Garcia, R.; Mujica, J.L. Costo-efectividad del dasatinib en el tratamiento de la leucemia mieloide crónica en pacientes resistentes al imatinib. CES Med. 2010, 2, 2215–9177. | spa |
| dcterms.references | Braun, T.P.; Eide, C.A.; Druker, B.J. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell 2020, 37, 530–542. | eng |
| dcterms.references | Avilés-Vázquez, S.; Chávez-González, M.; Mayani, H. Inhibidores de cinasas de tirosina (ICT): La nueva revolución en el tratamiento de la leucemia mieloide crónica (LMC). Gac. Méd. México 2013, 149, 646–654. | spa |
| dcterms.references | Jabbour, E.; Kantarjian, H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am. J. Hematol. 2022, 97, 1236–1256. | eng |
| dcterms.references | González, M.A.C.; Ayala-Sánchez, M.; Mayani, H. La leucemia mieloide crónica en el siglo XXI: Biología y tratamiento. Rev. Investig. Clín. 2009, 61, 221–232. | spa |
| dcterms.references | Delord, M.; Rousselot, P.; Cayuela, J.M.; Sigaux, F.; Guilhot, J.; Preudhomme, C.; Guilhot, F.; Loiseau, P.; Raffoux, E.; Geromin, D.; et al. High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget 2013, 4, 1582–1591. | eng |
| dcterms.references | Gambacorti-Passerini; Barni, R.; Marchesi, E.; Verga, M.; Rossi, F.; Rossi, F.; Pioltelli, P.; Pogliani, E.; Corneo, G.M. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. Br. J. Haematol. 2001, 112, 972–974. | eng |
| dcterms.references | Holtz, M.S.; Slovak, M.L.; Zhang, F.; Sawyers, C.L.; Forman, S.J.; Bhatia, R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002, 99, 3792–3800. | eng |
| dcterms.references | Cohen, P.; Cross, D.; Jänne, P.A. Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat. Rev. Drug Discov. 2021, 20, 551–569. | eng |
| dcterms.references | Claudiani, S.; Apperley, J.F. The argument for using imatinib in CML. Hematol. Am. Soc. Hematol. Educ. Program. 2018, 1, 161– 167. | eng |
| dcterms.references | Bhatia, R.; Holtz, M.; Niu, N.; Gray, R.; Snyder, D.S.; Sawyers, C.L.; Arber, D.A.; Slovak, M.L.; Forman, S.J. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101, 4701–4707. | eng |
| dcterms.references | Cortes, J.; De Souza, C.; Ayala-Sanchez, M.; Bendit, I.; Best-Aguilera, C.; Enrico, A.; Hamerschlak, N.; Pagnano, K.; Pasquini, R.; Meillon, L. Current patient management of chronic myeloid leukemia in Latin America: A study by the Latin American Leukemia Net (LALNET). Cancer 2010, 116, 4991–5000. | eng |
| dcterms.references | Hijiya, N.; Schultz, K.R.; Metzler, M.; Millot, F.; Suttorp, M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 2016, 127, 392–399. | eng |
| dcterms.references | Breccia, M.; Alimena, G. The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose. Expert. Opin. Pharmacother. 2011, 12, 2075–2087. | eng |
| dcterms.references | Cruz-Rico, J.; Garrido-Acosta, O.; Anguiano-Robledo, L.; Rodríguez-Wong, U.; Pérez-Cruz, E.; Sánchez-Navarrete, J.; Ruiz-Pérez, N.J.; Montes-Vera, M.D.R. Imatinib: Farmacocinética. Rev. Hosp. Jua. Mex. 2013, 80, 67–72. | eng |
| dcterms.references | Benchikh, S.; Bousfiha, A.; Hamouchi, A.E.; Soro, S.G.C.; Malki, A.; Nassereddine, S. Chronic myeloid leukemia: Cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution. Egypt. J. Med. Hum. Genet. Vol. 2022, 29, 1–13. | eng |
| dcterms.references | Gardner, E.R.; Burger, H.; van Schaik, R.H.; van Oosterom, A.T.; de Bruijn, E.A.; Guetens, G.; Prenen, H.; de Jong, F.A.; Baker, S.D.; Bates, S.E.; et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther. 2006, 80, 192–201. | eng |
| dcterms.references | Camargo, M.; Soto-Marín, M.I.; Zea, O.; Saavedra, D. Tratamiento con imatinib y el farmacogenotipo CYP3A4 en relación con la expansión clonal Ph(+) en leucemia mieloide crónica (LMC)*. Colombia Médica 2008, 30. 314-322. | spa |
| dcterms.references | Sailaja, K.; Rao, D.N.; Rao, D.R.; Vishnupriya, S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac. J. Cancer Prev. 2010, 11, 781–784. | eng |
| dcterms.references | Bedewy, A.M.L.; El-Maghraby, S.M. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? Hematology 2013, 18, 211–216. | eng |
| dcterms.references | Vaidya, S.; Ghosh, K.; Shanmukhaiah, C.; Vundint, B.R. Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. Eur. J. Pharmacol. 2015, 15, 124–130. | eng |
| dcterms.references | Maddin, N.; Husin, A.; Gan, S.H.; Aziz, B.A.; Ankathil, R. Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia. Oncol. Ther. 2016, 4, 303–314. | eng |
| dcterms.references | Saiz-Rodríguez, M.; Almenara, S.; Navares-Gómez, M.O.D.; Román, M.; Zubiaur, P.; Koller, D.; Santos, M.; Mejía, G.; Borobia, A.M.; Rodríguez-Antona, C.; et al. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. Biomedicines 2020, 8, 94. | eng |
| dcterms.references | Harivenkatesh, N.; Kumar, L.; Bakhshi, S.; Sharma, A.; Kabra, M.; Velpandian, T.; Gogia, A.; Shastri, S.S.; Gupta, Y.K. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? Leuk. Lymphoma 2017, 58, 2218–2226. | eng |
| dcterms.references | Akram, A.M.; Iqbal, Z.; Akhtar, T.; Khalid, A.M.; Sabar, M.F.; Qazi, M.H.; Aziz, Z.; Sajid, N.; Aleem, A.; Rasool, M.; et al. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression. Cancer Biol. Ther. 2017, 18, 214–221. | eng |
| dcterms.references | Hoemberger, M.; Pitsawong, W.; Kern, D. Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proc. Natl. Acad. Sci. USA 2020, 117, 19221–19227. | eng |
| dcterms.references | Minciacchi, V.R.; Kumar, R.; Krause, D.S. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells 2021, 10, 117. | eng |
| dcterms.references | Molloy, G.; O’Carroll, R.; Ferguson, E. Conscientiousness and Medication Adherence: A Meta-analysis. Ann. F Behav. Med. 2014, 47, 92–101. | eng |
| dcterms.references | Duval, S.; Tweedie, R. A Nonparametric Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis. J. Am. Stat. Assoc. 2000, 95, 89–98. | eng |
| dcterms.references | Vevea, J.L.; Woods, C.M. Publication Bias in Research Synthesis: Sensitivity Analysis Using a Priori Weight Functions. Psychol. Methods 2005, 10, 428–443. | eng |
| dcterms.references | Egger, M.; Schneider, S.G.D.M.; Minder, C. Bias in Meta-Analysis Detected by a Simple, Graphical Test. BMJ 1997, 315, 619. | eng |
| dcterms.references | Shadish, W.R.; Haddock, C.K. Combining Estimates of Effect Size. In The Handbook of Research Synthesis and Meta‐Analysis, 2nd ed.; Russell Sage Foundation: London, UK, 2009; pp. 257–277. | eng |
| dcterms.references | Hamed, N.A.M.; Neanea, H.; Ghanem, A.M.; Elgammal, M.M.A.; Samir, Y. Polymorphism of Human Organic Cationic Transporter1 (C480G) in Egyptian Chronic Myeloid Leukemia Patients on Imatinib. Am. J. Mol. Biol. 2018, 8, 83–91. | eng |
| dcterms.references | Elghannam, D.M.; Ibrahim, L.; Ebrahim, M.A.; Azmy, H.H.E. Association of MDR1 gene polymorphism(G2677T) with imatinib response in Egyptianchronic myeloid leukemia patients. Hematology 2013, 19, 123–128. | eng |
| dcterms.references | Wang, Q.; Jiang, Z.-P.; Zeng, J.; Zhu, Y.; Cai, H.-L.; Xiang, D.-X.; He, X.-L.S.Q.; Zhong, X.-L.; Xu, Q. Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia. J. Pharm. Pharm. Sci. 2020, 23, 1–205. | eng |
| dcterms.references | Au, A.; Baba, A.A.; Goh, A.S.; Fadilah, S.A.W.; Teh, H.R.A.; Ankathil, R. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed. Pharmacother, 2014, 6, 343–349. | eng |
| dcterms.references | De Lima, T.L.; Vivona, D.; Bueno, C.T.; Hirata, R.; Hirata, M.; Luchessi, A.; de Castro, F.A.; Chauffaille, M.D.L.; Zanichelli, M.; Chiattone, C.; et al. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med. Oncol. 2014, 31, 851. | eng |
| dcterms.references | Alves, R.; Gonçalves, A.C.; Jorge, J.; Marques, G.; Ribeiro, A.B.; Tenreiro, R.; Coucelo, M.; Diamond, J.; Oliveiros, B.; Pereira, A.; et al. Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis. Int. J. Mol. Sci. 2022, 23, 9815. | eng |
| dcterms.references | Nouri, N.; Mehrzad, V.; Khalaj, Z.; Zaker, E.; Zare, F.; Abbasi, E.; Khosravi, M.; Kalanta, S.M.; Salehi, M. Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients. Egypt. J. Med. Hum. Genet. 2023, 24, 1–7. | eng |
| dcterms.references | Leongómez, J.D. Meta-análisis de correlaciones y meta-regresión en R: Guía práctica. MetaArXiv 2023, 4, 1-61. https://doi.org/10.31222/osf.io/yaxd4. | spa |
| dcterms.references | Borenstein, M.; Higgns, H.L.V.J.P.T.; Rothstein, H.R. Identifying and Quantifying Heterogeneity. In Introduction to Meta‐Analysis; Wiley: Hoboken, NJ, USA, 2009; pp. 107–125. | eng |
| dcterms.references | Takahashi, N.; Miura, M.; Scott, H.; Kameoka, Y.; Tagawa, H.; Saitoh, H.; Fujishima, N.; Yoshioka, T.; Hirokawa, M.; Sawada, K. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Human Gen. 2010, 55, 731–737. | eng |
| dcterms.references | Vine, J.; Cohen, S.; Ruchlemer, R.; Goldschmidt, N.; Levin, M.; Libster, D.; Gural, A.; Gatt, M.; Lavie, D.; Ben-Yehuda, D.; et al. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: Correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk. Lymphoma 2014, 55, 2525–2531. | eng |
| dcterms.references | Kim, D.; Sriharsha, L.; Xu, W.; Kamel-Reid, S.; Liu, X.; Siminovitch, K.; Messner, H.A.; Lipton, J.H. Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia. Clin. Cancer Res. 2009, 15, 4750–4758. | eng |
| dcterms.references | Van Den, M.; Heuvel-Eibrink, E.; Weimer, M.; De Boevere, B.; Van Der Holt, P.; Vossebeld, R.; Pieters, R.S. MDR1 gene related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 2001, 97, 3605–3611. | eng |
| dcterms.references | Khorashad, J.; de Lavallade, H.; Apperley, J.; Milojkovic, D.; Reid, A.; Bua, M.; Szydlo, R.; Olavarria, E.; Kaeda, J.; Goldman, J.; et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J. Clin. Oncol. 2008, 26, 4806–4813. | eng |
| dcterms.references | Gurney, H.; Wong, M.; Balleine, R.L.; Rivory, L.P.; McLachlan, A.J.; Hoskins, J.M.; Wilcken, N.; Clarke, C.L.; Mann, G.J.; Collins, M.; et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 2007, 82, 33–40. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | |
| sb.programa | Maestría en Genética | spa |
| sb.sede | Sede Barranquilla | spa |